Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02786173 · ClinicalTrials.gov registry record
Peripheral Registry of Endovascular Clinical Outcomes "The PRIME Registry"
A clinical trial, sponsored by Metro Health, Michigan.
- Completed
- Registry status
- 1,000
- Enrollment target
NCT02786173: Completed study, sponsored by Metro Health, Michigan.
NCT02786173 is a clinical trial that has completed, run by Metro Health, Michigan. The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02786173 has completed, sponsored by Metro Health, Michigan.
- COMPLETED
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
The PRIME Registry is a multi-center, observational study designed to evaluate immediate and long-term outcomes (36 months) of endovascular revascularization in patients with critical limb ischemia (CLI) and advanced peripheral artery disease (PAD).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2013-01 |
| Est. Completion | 2021-11-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02786173
The ClinicalTrials.gov registry entry for NCT02786173 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Metro Health, Michigan, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02786173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02786173 about?
NCT02786173 is a clinical study titled "Peripheral Registry of Endovascular Clinical Outcomes "The PRIME Registry"". The PRIME Registry is a multi-center, observational study designed to evaluate immediate and long-term outcomes (36 months) of endovascular revascularization in patients with critical limb ischemia (CLI) and advanced peripheral artery disease (PAD).
What is the current status of trial NCT02786173?
This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2013-01. Estimated completion is 2021-11-05.
Who is sponsoring clinical trial NCT02786173?
This trial is sponsored by Metro Health, Michigan, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.